Ability of troponins to predict adverse outcomes in patients with renal insufficiency and suspected acute coronary syndromes: case-matched study

Ability of troponins to predict adverse outcomes in patients with renal insufficiency and suspected acute coronary syndromes: case-matched study Original Research Article Pages 471-478 Frederick Van Lente, Ellen S. McErlean, Sue A. DeLuca, W. Franklin Peacock, J. Sunil Rao, Steven E. Nissen Close Close preview | PDF (220 K) | Related articles | Related reference work articles AbstractAbstract | Figures/TablesFigures/Tables | ReferencesReferences Abstract Objectives The purpose of this study was to investigate the utility of cardiac troponin T and troponin I for predicting outcomes in patients presenting with suspected acute coronary syndromes and renal insufficiency relative to that observed in similar patients without renal disease. Background Cardiac troponin T and troponin I have shown promise as tools for risk stratification of patients with acute coronary syndromes. However, there is uncertainty regarding their cardiac specificity and utility in patients with renal disease. Methods We measured troponin T, troponin I and creatine kinase MB in 51 patients presenting with suspected acute coronary syndromes and renal insufficiency and in 102 patients without evidence of renal disease matched for the same peak troponin T or I value, selected from larger patient cohort. Blood samples were obtained at presentation to an emergency room 4 hours, 8 hours and 16 hours later. The ability of biochemical markers to predict adverse outcomes in both groups including infarction, recurrent ischemia, bypass surgery, heart failure, stroke, death or positive angiography/angioplasty during hospitalization and at six months was assessed by receiver-operator curve analysis. The performance of both troponins was compared between groups. Results Thirty-five percent of patients in the renal group and 45% of patients in the nonrenal group experienced an adverse initial outcome; over 50% of patients in all groups had experienced an adverse outcome by 6 months, but these differences were not significant. The are under the curve (AUC) for the ROC curve for troponin T as predictor of initial outcomes was significantly lower in the renal group than in the nonrenal group: 0.56 ± 0.07 and 0.75 ± 0.07, respectively. The are under the curve was also significantly lower in the renal group compared with the nonrenal group for troponin T as predictor of six month outcomes: 0.59 ± 0.07 and 0.74 ± 0.07, respectively. The are under the curve was also significantly lower in the renal group compared to the nonrenal group for troponin I as predictor of both initial and six month outcomes: 0.54 ± 0.06 vs. 0.71 ± 0.07 and 0.53 ± 0.06 vs. 0.65 ± 0.07, respectively. The sensitivity of troponin T for both initial and six month adverse outcomes was significantly lower in the renal group than in the nonrenal group at similar level of specificity (0.87): 0.29 vs. 0.60 and 0.45 vs. 0.56, respectively. Troponin I also exhibited similar differences in sensitivity in the renal group (0.29 vs. 0.50 and 0.33 vs. 0.40, respectively). Conclusions The ability of cardiac troponin T and troponin I to predict risk for subsequent adverse outcomes in patients presenting with suspected acute coronary syndromes is reduced in the presence of renal insufficiency. Article Outline • Methods • Patients and study protocol • Diagnosis and outcome definitions • Biochemical markers • Statistical analysis • Results • Clinical characteristics • Troponin detection of in-hospital adverse outcomes • Troponin detection of six month adverse outcomes • Discussion • Noncardiac factors that could affect cardiac troponin values in patients with renal insufficiency • Usefulness of cTnT and cTnI in risk stratification of patients presenting with acute coronary syndromes and renal disease • Comparison of troponin T, troponin I and CK-MB • Study limitations • Conclusions • References